

SPRING GROUP MEETING

Seattle

Barlogie-Salmon Myeloma Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

Barlogie-Salmon Myeloma Committee

Leadership

Chair:Robert Z. Orlowski, MD, PhD
 Vice-Chair:Sikander Ailawadhi, MD
 Vice-Chair:Jing Christine Ye, MD, MSc
 Executive Officer:Susan M. O'Brien, MD
 Statisticians:Antje Hoering, PhD
Rachael Sexton, MS
Adam Rosenthal, MS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation:Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging:Eric M. Rohren, MD, PhD
 Pathology:Pei Lin, MD
 Early Therapeutics:Frits van Rhee, MD, PhD

Designates

DEI Champion: Manuel Ricardo Espinoza-Gutierrez, MD
 Digital Engagement: TBD
 NCORP Representative:Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators:Aubrey Gilmore, BA
Daria Chugina, MD, CCRPS
Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse: Teresa Witcher, BSN, RN
 Patient Advocate: Paul Gater, MPhil
Jack Aiello, MS (Emeritus)
 Pharmaceutical Science: Craig Elg, PharmD
Ila M. Saunders, PharmD
 Sr. Protocol Project Manager: Sharon Palmer
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, April 6, 2024 9:30 a.m. - 11:30 a.m.
 Room: Elwha B (Level 5)

Active Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and P. Hari. Activated: 6/27/19.

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)." Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 05/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/01/2023.

EAA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

EAA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

Developing Studies-Post Triage

S2416, "Phase III Study of Optimal Induction and MRD Driven Maintenance Therapy for Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and K. Gowin.

Closed Studies-Updates

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Santhorawala. Activated: 3/08/18; Closed: 9/30/19.

Barlogie-Salmon Myeloma Committee

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S2209 Clinical trial design change implementation for inclusive studies.
Espinoza Gutarra M, Aiello J, Orlowski R, Ailawadhi S. Lancet Hematology
Dec;10(12):e953-e954, 2023.
<https://pubmed.ncbi.nlm.nih.gov/38030317/>

Submitted Manuscripts

None this cycle

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1803	S2209	EAA173	EAA181
Ascension Providence Hospitals - Southfield	2	-	1	-
Banner University Medical Center - Tucson	8	-	-	5
Boston Medical Center	5	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	24	-	3	-
Cancer Research for the Ozarks NCORP	2	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	-	-	-
Cedars-Sinai Medical Center	6	-	-	-
City of Hope Comprehensive Cancer Center	97	-	-	-
Columbus NCI Community Oncology Research Program	8	-	-	-
CommonSpirit Health Research Institute	3	2	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	6	-
Froedtert and the Medical College of Wisconsin LAPS	7	-	-	-
Georgia NCI Community Oncology Research Program	13	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-
Heartland Cancer Research NCORP	14	1	-	-
Houston Methodist Hospital	4	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	41	-	-	-
Lahey Hospital and Medical Center	3	-	-	-
Loyola University Medical Center	22	-	3	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	2
Medical University of South Carolina Minority Underserved NCORP	43	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-
Michigan Cancer Research Consortium NCORP	7	-	-	-
Moffitt Cancer Center	41	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	1	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1803	S2209	EAA173	EAA181
New Mexico Minority Underserved NCORP	11	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	4	-	-	-
Oregon Health and Science University	26	-	3	9
Pacific Cancer Research Consortium NCORP	16	1	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-
UC Davis Comprehensive Cancer Center LAPS	21	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	10	-	-	-
University of Arkansas for Medical Sciences	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	30	-	-	-
University of Kentucky/Markey Cancer Center	3	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	14	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-
University of Rochester LAPS	15	-	-	1
University of Texas Health Science Center at San Antonio	14	-	-	-
University of Texas MD Anderson Cancer Center LAPS	24	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	4	1
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	13	-	-	-
Wisconsin NCI Community Oncology Research Program	19	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	7
ALLIANCE	184	1	-	-
CCTG	6	-	-	-
ECOG-ACRIN	156	1	-	-
NRG	87	-	-	-
Total	1,049	8	26	30

